ACCESS REALMONEY
Icahn Loses Battle for Biogen Board Seats
The biotech company's slate of nominees wins the vote.
Related Topics: Drugs | Health Care | Biotech
12:08PM 06/19/08
Biotech Review: Elan's Alzheimer's Drug
The promising data sent shares soaring Tuesday; here's what investors need to know now.
Related Topics: Biotech | Drugs | Health Care
07:09AM 06/18/08
Stocks in the U.S. struggled for much of the session Tuesday and closed lower as investors shrugged off decent monthly inflation data and an earnings beat from Goldman Sachs GS.
Related Topics: Markets | Energy | Technology | Retail | Telecom | Biotech | Software | Media | Consumer Goods
04:37PM 06/17/08
A Quiet Medicines Co. Raises Questions
The CEO last week disclosed a regulatory hiccup in its application for Cleviprex, months after the FDA first informed the company of a delay.
Related Topics: Drugs | Biotech | Health Care
07:46AM 06/17/08
Elan Reports Mixed Alzheimer Results
The Elan and Wyeth drug was at least partially effective in a subgroup of patients lacking a higher genetic risk for developing Alzheimer's.
Related Topics: Health Care | Biotech | Drugs
06:49AM 06/17/08
Acadia Shares Sink on Failed Study
A midstage trial for schizophrenia drug ACP-104 didn't meet its primary or secondary endpoints.
Related Topics: Drugs | Health Care | Biotech
11:02AM 06/16/08
Biotech Watch: Elan's Alzheimer's Drug Data
The potential market for bapineuzumab is massive. Here's how to sort the trial data when released.
Related Topics: Health Care | Biotech | Drugs
12:41PM 06/13/08
Biotech-Stock Mailbag: Sangamo
Weighing chances for Sangamo's lead pipeline drug, and more.
Related Topics: Biotech | Fundamental Analysis
06:59AM 06/13/08
Stocks in New York closed in the green Thursday, though the major averages fell off their session highs as oil rebounded from an early decline and Yahoo! YHOO shares sank in the afternoon.
Related Topics: Markets | Telecom | Financial Services | Media | Retail | Biotech | Banks | Technology
05:00PM 06/12/08
Invitrogen, Applied Biosystems Ink Merger
The biotech will pay $38 a share, or about $6.7 billion, for the instruments company in a combination of cash and stock.
Related Topics: Drugs | M&A | Health Care | Biotech
09:37AM 06/12/08
Genentech Settles Patent Dispute With MedImmune
Genentech said it is not updating its royalty revenue guidance.
Related Topics: Drugs | Biotech | Health Care
06:08PM 06/11/08
Court Docs: Icahn Mulled $76-$82/Share for Biogen
Bloomberg reports the activist investor revealed he might have been willing to pay up to $15 billion last fall.
Related Topics: Health Care | Drugs | Biotech
12:07PM 06/11/08
Biotech Notebook: Vertex, Medicines Co.
Uncertain regulation hangs on Vertex's telaprevir, The Medicines Co. remains mum on Cleviprex and a summer biotech-stock watch list.
Related Topics: Health Care | Biotech | Drugs
10:09AM 06/10/08
Vertex Unveils More Upbeat Hep C Drug Data
Its telaprevir reduced levels of the virus down to undetectable levels in 52% of difficult-to-treat patients.
Related Topics: Drugs | Biotech | Health Care
10:28AM 06/09/08
How to Hedge: Indevus Pharmaceuticals
What if you could get an insurance policy for your portfolio? With hedging, you can. Here's how.
Related Topics: Biotech | ETFs | Strategy | Personal Finance | Options/Futures Basics | Short-Selling
01:33PM 06/06/08
symbol throughout our site to look up items.
